Skip to main content
SpringerLink
Log in

Hepatotoxicity of Alogliptin

  • Letter to the Editor
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Scheen AJ. Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus. Clin Pharmacokinet. 2014 [Epub ahead of print].

  2. Scott LJ. Alogliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs. 2010;70(15):2051–72.

    Article  PubMed  CAS  Google Scholar 

  3. Food and Drug Administration. Alogliptin, “Other Reviews”. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000OtherRedt.pdf. Accessed 18 Aug 2014.

  4. European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) assessment report. Vipidia (alogliptin). 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002182/WC500152273.pdf. Accessed 18 Aug 2014.

  5. Food and Drug Administration. Approved Drug Products. Alogliptin (2013). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/022271s000lbl.pdf. Accessed 18 Aug 2014.

  6. European Medicines Agency. Alogliptin product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002182/WC500152271.pdf. Accessed 18 Aug 2014.

  7. Food and Drug Administration. Alogliptin Medical Review. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000MedRedt.pdf. Accessed 18 Aug 2014.

  8. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.

    Article  PubMed  CAS  Google Scholar 

  9. Food and Drug Administration. Guidance for Industry. Drug-Induced Liver Injury: Premarketing Clinical Evaluation. 2009. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM174090.pdf. Accessed 18 Aug 2014.

  10. National Institutes of Health. National Library of Medicine. MedlinePlus. ALT. http://www.nlm.nih.gov/medlineplus/ency/article/003473.htm. Accessed 18 Aug 2014.

  11. The Merck Manual, Professional Edition. Normal Laboratory Values: Blood, Plasma, and Serum. http://www.merckmanuals.com/professional/appendixes/normal_laboratory_values/blood_tests_normal_values.html. Accessed 18 Aug 2014.

Download references

Author information

Authors and Affiliations

  1. Public Citizen, Washington, DC, USA

    Elizabeth Barbehenn, Sammy Almashat, Michael Carome & Sidney Wolfe

Authors
  1. Elizabeth Barbehenn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sammy Almashat
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Carome
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sidney Wolfe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Barbehenn.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Barbehenn, E., Almashat, S., Carome, M. et al. Hepatotoxicity of Alogliptin. Clin Pharmacokinet 53, 1055–1056 (2014). https://doi.org/10.1007/s40262-014-0199-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-014-0199-1

Keywords

Search

Navigation